December 03, 2025
2 min watch
Healio spoke with Marlyn Mayo, MD, about increased research focused on symptoms of primary sclerosing cholangitis presented at The Liver Meeting, as well as treatments being investigated.
“Traditionally, we haven’t paid a lot of attention to symptoms in PSC, except when patients have acute cholangitis,” Mayo, professor of internal medicine at UT Southwestern Medical Center, said. “But there were a number of posters looking at prevalence of pruritus and fatigue, showing that it’s indeed extremely common, underrecognized by physicians and vastly undertreated.”
Mayo highlighted data from the ongoing phase 2 ELMWOOD open-label extension trial of elafibranor (Iqirvo, Ipsen) in patients with PSC, which showed “stabilization of fibrosis and continued biochemical improvement.”
More importantly, she noted patients who received elafibranor achieved “encouraging” improvement in the Worst Itch-Numerical Rating Scale.
“I was happy to see that there were a number of presentations on primary sclerosing cholangitis,” she said. “In the past, this has been a situation where we say, ‘This is a terrible disease. We have nothing to treat it.’ But all of that is rapidly changing.”
For more information:
Marlyn Mayo, MD, can be reached at marlyn.mayo@utsouthwestern.edu.
Sources/Disclosures
Source:
Healio Interviews
Reference:
- Bowlus C, et al. Long-term data of elafibranor in primary sclerosing cholangitis: Interim safety and efficacy data from the ongoing open-label extension of the ELMWOOD phase II trial. Presented at: The Liver Meeting; Nov. 7-11, 2025; Washington (hybrid meeting).
Disclosures:
Mayo reports consulting for and conducting clinical trials for Ipsen and Mirum Pharmaceuticals.
Ask a clinical question and tap into Healio AI’s knowledge base.
- PubMed, enrolling/recruiting trials, guidelines
- Clinical Guidance, Healio CME, FDA news
- Healio’s exclusive daily news coverage of clinical data
